IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer

Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)–LTβ receptor (LTβR) pathway 1 , the inflammatory signals and cell...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature (London) Jg. 638; H. 8052; S. 1076 - 1084
Hauptverfasser: Amisaki, Masataka, Zebboudj, Abderezak, Yano, Hiroshi, Zhang, Siqi Linsey, Payne, George, Chandra, Adrienne Kaya, Yu, Rebecca, Guasp, Pablo, Sethna, Zachary M., Ohmoto, Akihiro, Rojas, Luis A., Cheng, Charlotte, Waters, Theresa, Solovyov, Alexander, Martis, Stephen, Doane, Ashley S., Reiche, Charlotte, Bruno, Emmanuel M., Milighetti, Martina, Soares, Kevin, Odgerel, Zagaa, Moral, John Alec, Zhao, Julia N., Gönen, Mithat, Gardner, Rui, Tumanov, Alexei V., Khan, Abdul G., Vergnolle, Olivia, Nyakatura, Elisabeth K., Lorenz, Ivo C., Baca, Manuel, Patterson, Erin, Greenbaum, Benjamin, Artis, David, Merghoub, Taha, Balachandran, Vinod P.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 27.02.2025
Nature Publishing Group
Schlagworte:
ISSN:0028-0836, 1476-4687, 1476-4687
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)–LTβ receptor (LTβR) pathway 1 , the inflammatory signals and cells that induce TLSs remain incompletely identified. Here we show that interleukin-33 (IL-33), the alarmin released by inflamed tissues 2 , induces TLSs. In mice, Il33 deficiency severely attenuates inflammation- and LTβR-activation-induced TLSs in models of colitis and pancreatic ductal adenocarcinoma (PDAC). In PDAC, the alarmin domain of IL-33 activates group 2 innate lymphoid cells (ILC2s) expressing LT that engage putative LTβR + myeloid organizer cells to initiate tertiary lymphoneogenesis. Notably, lymphoneogenic ILC2s migrate to PDACs from the gut, can be mobilized to PDACs in different tissues and are modulated by gut microbiota. Furthermore, we detect putative lymphoneogenic ILC2s and IL-33-expressing cells within TLSs in human PDAC that correlate with improved prognosis. To harness this lymphoneogenic pathway for immunotherapy, we engineer a recombinant human IL-33 protein that expands intratumoural lymphoneogenic ILC2s and TLSs and demonstrates enhanced anti-tumour activity in PDAC mice. In summary, we identify the molecules and cells of a druggable pathway that induces inflammation-triggered TLSs. More broadly, we reveal a lymphoneogenic function for alarmins and ILC2s. IL-33 induces tertiary lymphoid structures.
AbstractList Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)–LTβ receptor (LTβR) pathway 1 , the inflammatory signals and cells that induce TLSs remain incompletely identified. Here we show that interleukin-33 (IL-33), the alarmin released by inflamed tissues 2 , induces TLSs. In mice, Il33 deficiency severely attenuates inflammation- and LTβR-activation-induced TLSs in models of colitis and pancreatic ductal adenocarcinoma (PDAC). In PDAC, the alarmin domain of IL-33 activates group 2 innate lymphoid cells (ILC2s) expressing LT that engage putative LTβR + myeloid organizer cells to initiate tertiary lymphoneogenesis. Notably, lymphoneogenic ILC2s migrate to PDACs from the gut, can be mobilized to PDACs in different tissues and are modulated by gut microbiota. Furthermore, we detect putative lymphoneogenic ILC2s and IL-33-expressing cells within TLSs in human PDAC that correlate with improved prognosis. To harness this lymphoneogenic pathway for immunotherapy, we engineer a recombinant human IL-33 protein that expands intratumoural lymphoneogenic ILC2s and TLSs and demonstrates enhanced anti-tumour activity in PDAC mice. In summary, we identify the molecules and cells of a druggable pathway that induces inflammation-triggered TLSs. More broadly, we reveal a lymphoneogenic function for alarmins and ILC2s. IL-33 induces tertiary lymphoid structures.
Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically infamed tissues, including tumours. Although TLSs form due to infammation-triggered activation of the lymphotoxin (LT)-LTβ receptor (LTβR) pathway1 , the infammatory signals and cells that induce TLSs remain incompletely identifed. Here we show that interleukin-33 (IL-33), the alarmin released by infamed tissues2 , induces TLSs. In mice, Il33 defciency severely attenuates infammation- and LTβR-activation-induced TLSs in models of colitis and pancreatic ductal adenocarcinoma (PDAC). In PDAC, the alarmin domain of IL-33 activates group 2 innate lymphoid cells (ILC2s) expressing LT that engage putative LTβR+ myeloid organizer cells to initiate tertiary lymphoneogenesis. Notably, lymphoneogenic ILC2s migrate to PDACs from the gut, can be mobilized to PDACs in diferent tissues and are modulated by gut microbiota. Furthermore, we detect putative lymphoneogenic ILC2s and IL-33-expressing cells within TLSs in human PDAC that correlate with improved prognosis. To harness this lymphoneogenic pathway for immunotherapy, we engineer a recombinant human IL-33 protein that expands intratumoural lymphoneogenic ILC2s and TLSs and demonstrates enhanced anti-tumour activity in PDAC mice. In summary, we identify the molecules and cells of a druggable pathway that induces infammationtriggered TLSs. More broadly, we reveal a lymphoneogenic function for alarmins and ILC2s.
Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)-LTβ receptor (LTβR) pathway , the inflammatory signals and cells that induce TLSs remain incompletely identified. Here we show that interleukin-33 (IL-33), the alarmin released by inflamed tissues , induces TLSs. In mice, Il33 deficiency severely attenuates inflammation- and LTβR-activation-induced TLSs in models of colitis and pancreatic ductal adenocarcinoma (PDAC). In PDAC, the alarmin domain of IL-33 activates group 2 innate lymphoid cells (ILC2s) expressing LT that engage putative LTβR myeloid organizer cells to initiate tertiary lymphoneogenesis. Notably, lymphoneogenic ILC2s migrate to PDACs from the gut, can be mobilized to PDACs in different tissues and are modulated by gut microbiota. Furthermore, we detect putative lymphoneogenic ILC2s and IL-33-expressing cells within TLSs in human PDAC that correlate with improved prognosis. To harness this lymphoneogenic pathway for immunotherapy, we engineer a recombinant human IL-33 protein that expands intratumoural lymphoneogenic ILC2s and TLSs and demonstrates enhanced anti-tumour activity in PDAC mice. In summary, we identify the molecules and cells of a druggable pathway that induces inflammation-triggered TLSs. More broadly, we reveal a lymphoneogenic function for alarmins and ILC2s.
Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)–LTβ receptor (LTβR) pathway1, the inflammatory signals and cells that induce TLSs remain incompletely identified. Here we show that interleukin-33 (IL-33), the alarmin released by inflamed tissues2, induces TLSs. In mice, Il33 deficiency severely attenuates inflammation- and LTβR-activation-induced TLSs in models of colitis and pancreatic ductal adenocarcinoma (PDAC). In PDAC, the alarmin domain of IL-33 activates group 2 innate lymphoid cells (ILC2s) expressing LT that engage putative LTβR+ myeloid organizer cells to initiate tertiary lymphoneogenesis. Notably, lymphoneogenic ILC2s migrate to PDACs from the gut, can be mobilized to PDACs in different tissues and are modulated by gut microbiota. Furthermore, we detect putative lymphoneogenic ILC2s and IL-33-expressing cells within TLSs in human PDAC that correlate with improved prognosis. To harness this lymphoneogenic pathway for immunotherapy, we engineer a recombinant human IL-33 protein that expands intratumoural lymphoneogenic ILC2s and TLSs and demonstrates enhanced anti-tumour activity in PDAC mice. In summary, we identify the molecules and cells of a druggable pathway that induces inflammation-triggered TLSs. More broadly, we reveal a lymphoneogenic function for alarmins and ILC2s. IL-33 induces tertiary lymphoid structures.
Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)-LTβ receptor (LTβR) pathway1, the inflammatory signals and cells that induce TLSs remain incompletely identified. Here we show that interleukin-33 (IL-33), the alarmin released by inflamed tissues2, induces TLSs. In mice, Il33 deficiency severely attenuates inflammation- and LTβR-activation-induced TLSs in models of colitis and pancreatic ductal adenocarcinoma (PDAC). In PDAC, the alarmin domain of IL-33 activates group 2 innate lymphoid cells (ILC2s) expressing LT that engage putative LTβR+ myeloid organizer cells to initiate tertiary lymphoneogenesis. Notably, lymphoneogenic ILC2s migrate to PDACs from the gut, can be mobilized to PDACs in different tissues and are modulated by gut microbiota. Furthermore, we detect putative lymphoneogenic ILC2s and IL-33-expressing cells within TLSs in human PDAC that correlate with improved prognosis. To harness this lymphoneogenic pathway for immunotherapy, we engineer a recombinant human IL-33 protein that expands intratumoural lymphoneogenic ILC2s and TLSs and demonstrates enhanced anti-tumour activity in PDAC mice. In summary, we identify the molecules and cells of a druggable pathway that induces inflammation-triggered TLSs. More broadly, we reveal a lymphoneogenic function for alarmins and ILC2s.Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)-LTβ receptor (LTβR) pathway1, the inflammatory signals and cells that induce TLSs remain incompletely identified. Here we show that interleukin-33 (IL-33), the alarmin released by inflamed tissues2, induces TLSs. In mice, Il33 deficiency severely attenuates inflammation- and LTβR-activation-induced TLSs in models of colitis and pancreatic ductal adenocarcinoma (PDAC). In PDAC, the alarmin domain of IL-33 activates group 2 innate lymphoid cells (ILC2s) expressing LT that engage putative LTβR+ myeloid organizer cells to initiate tertiary lymphoneogenesis. Notably, lymphoneogenic ILC2s migrate to PDACs from the gut, can be mobilized to PDACs in different tissues and are modulated by gut microbiota. Furthermore, we detect putative lymphoneogenic ILC2s and IL-33-expressing cells within TLSs in human PDAC that correlate with improved prognosis. To harness this lymphoneogenic pathway for immunotherapy, we engineer a recombinant human IL-33 protein that expands intratumoural lymphoneogenic ILC2s and TLSs and demonstrates enhanced anti-tumour activity in PDAC mice. In summary, we identify the molecules and cells of a druggable pathway that induces inflammation-triggered TLSs. More broadly, we reveal a lymphoneogenic function for alarmins and ILC2s.
Author Balachandran, Vinod P.
Sethna, Zachary M.
Odgerel, Zagaa
Yano, Hiroshi
Yu, Rebecca
Gardner, Rui
Patterson, Erin
Ohmoto, Akihiro
Bruno, Emmanuel M.
Tumanov, Alexei V.
Waters, Theresa
Lorenz, Ivo C.
Artis, David
Zebboudj, Abderezak
Solovyov, Alexander
Doane, Ashley S.
Cheng, Charlotte
Chandra, Adrienne Kaya
Milighetti, Martina
Nyakatura, Elisabeth K.
Khan, Abdul G.
Baca, Manuel
Greenbaum, Benjamin
Moral, John Alec
Gönen, Mithat
Merghoub, Taha
Soares, Kevin
Vergnolle, Olivia
Guasp, Pablo
Rojas, Luis A.
Reiche, Charlotte
Amisaki, Masataka
Payne, George
Martis, Stephen
Zhao, Julia N.
Zhang, Siqi Linsey
Author_xml – sequence: 1
  givenname: Masataka
  orcidid: 0000-0003-4153-4036
  surname: Amisaki
  fullname: Amisaki, Masataka
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 2
  givenname: Abderezak
  orcidid: 0000-0002-4708-5211
  surname: Zebboudj
  fullname: Zebboudj, Abderezak
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 3
  givenname: Hiroshi
  orcidid: 0000-0002-3098-2629
  surname: Yano
  fullname: Yano, Hiroshi
  organization: Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Friedman Center for Nutrition and Inflammation, Weill Cornell Medicine, Cornell University, Allen Discovery Center for Neuroimmune Interactions, Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Cornell University, Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University
– sequence: 4
  givenname: Siqi Linsey
  orcidid: 0009-0001-4436-2746
  surname: Zhang
  fullname: Zhang, Siqi Linsey
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 5
  givenname: George
  surname: Payne
  fullname: Payne, George
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 6
  givenname: Adrienne Kaya
  surname: Chandra
  fullname: Chandra, Adrienne Kaya
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 7
  givenname: Rebecca
  surname: Yu
  fullname: Yu, Rebecca
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 8
  givenname: Pablo
  orcidid: 0000-0002-3655-916X
  surname: Guasp
  fullname: Guasp, Pablo
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 9
  givenname: Zachary M.
  surname: Sethna
  fullname: Sethna, Zachary M.
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center
– sequence: 10
  givenname: Akihiro
  surname: Ohmoto
  fullname: Ohmoto, Akihiro
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 11
  givenname: Luis A.
  orcidid: 0000-0001-9218-4086
  surname: Rojas
  fullname: Rojas, Luis A.
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 12
  givenname: Charlotte
  surname: Cheng
  fullname: Cheng, Charlotte
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 13
  givenname: Theresa
  surname: Waters
  fullname: Waters, Theresa
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 14
  givenname: Alexander
  surname: Solovyov
  fullname: Solovyov, Alexander
  organization: Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center
– sequence: 15
  givenname: Stephen
  orcidid: 0000-0003-1735-2347
  surname: Martis
  fullname: Martis, Stephen
  organization: Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center
– sequence: 16
  givenname: Ashley S.
  surname: Doane
  fullname: Doane, Ashley S.
  organization: Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center
– sequence: 17
  givenname: Charlotte
  surname: Reiche
  fullname: Reiche, Charlotte
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 18
  givenname: Emmanuel M.
  orcidid: 0000-0003-2885-1133
  surname: Bruno
  fullname: Bruno, Emmanuel M.
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 19
  givenname: Martina
  orcidid: 0000-0003-4170-8796
  surname: Milighetti
  fullname: Milighetti, Martina
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center
– sequence: 20
  givenname: Kevin
  orcidid: 0000-0002-0406-017X
  surname: Soares
  fullname: Soares, Kevin
  organization: Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center
– sequence: 21
  givenname: Zagaa
  surname: Odgerel
  fullname: Odgerel, Zagaa
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 22
  givenname: John Alec
  surname: Moral
  fullname: Moral, John Alec
  organization: Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 23
  givenname: Julia N.
  orcidid: 0000-0002-4352-7748
  surname: Zhao
  fullname: Zhao, Julia N.
  organization: Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– sequence: 24
  givenname: Mithat
  orcidid: 0000-0001-8683-8477
  surname: Gönen
  fullname: Gönen, Mithat
  organization: Department of Biostatistics & Epidemiology, Memorial Sloan Kettering Cancer Center
– sequence: 25
  givenname: Rui
  orcidid: 0000-0002-7270-5136
  surname: Gardner
  fullname: Gardner, Rui
  organization: Flow Cytometry Core Facility, Memorial Sloan Kettering Cancer Center
– sequence: 26
  givenname: Alexei V.
  surname: Tumanov
  fullname: Tumanov, Alexei V.
  organization: Department of Microbiology, Immunology & Molecular Genetics, University of Texas Health Science Center at San Antonio
– sequence: 27
  givenname: Abdul G.
  surname: Khan
  fullname: Khan, Abdul G.
  organization: Tri-Institutional Therapeutics Discovery Institute
– sequence: 28
  givenname: Olivia
  orcidid: 0000-0001-6885-6145
  surname: Vergnolle
  fullname: Vergnolle, Olivia
  organization: Tri-Institutional Therapeutics Discovery Institute
– sequence: 29
  givenname: Elisabeth K.
  surname: Nyakatura
  fullname: Nyakatura, Elisabeth K.
  organization: Tri-Institutional Therapeutics Discovery Institute
– sequence: 30
  givenname: Ivo C.
  surname: Lorenz
  fullname: Lorenz, Ivo C.
  organization: Tri-Institutional Therapeutics Discovery Institute
– sequence: 31
  givenname: Manuel
  surname: Baca
  fullname: Baca, Manuel
  organization: Tri-Institutional Therapeutics Discovery Institute
– sequence: 32
  givenname: Erin
  surname: Patterson
  fullname: Patterson, Erin
  organization: The Olayan Center for Cancer Vaccines, Memorial Sloan Kettering Cancer Center
– sequence: 33
  givenname: Benjamin
  orcidid: 0000-0001-6153-8793
  surname: Greenbaum
  fullname: Greenbaum, Benjamin
  organization: Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, Department of Biostatistics & Epidemiology, Memorial Sloan Kettering Cancer Center, The Olayan Center for Cancer Vaccines, Memorial Sloan Kettering Cancer Center, Physiology, Biophysics & Systems Biology, Weill Cornell Medicine, Weill Cornell Medical College
– sequence: 34
  givenname: David
  orcidid: 0000-0002-1753-4100
  surname: Artis
  fullname: Artis, David
  organization: Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Friedman Center for Nutrition and Inflammation, Weill Cornell Medicine, Cornell University, Allen Discovery Center for Neuroimmune Interactions, Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Cornell University, Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University
– sequence: 35
  givenname: Taha
  orcidid: 0000-0002-1518-5111
  surname: Merghoub
  fullname: Merghoub, Taha
  organization: Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, Weill Cornell Medical College, Parker Institute for Cancer Immunotherapy, Weill Cornell Medicine, Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine
– sequence: 36
  givenname: Vinod P.
  orcidid: 0000-0002-2956-223X
  surname: Balachandran
  fullname: Balachandran, Vinod P.
  email: balachav@mskcc.org
  organization: Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, The Olayan Center for Cancer Vaccines, Memorial Sloan Kettering Cancer Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39814891$$D View this record in MEDLINE/PubMed
BookMark eNp9UU1r3DAQFSWl2aT9Az0UQy-9qJGsT59KWdpmYUkv6VnI0jhR8MpbSQ7k31fuJmmaQ0AwgnnvzZt5J-goThEQek_JZ0qYPsucCi0xaTkmmrcSi1doRbmSmEutjtCKkFbXFpPH6CTnG0KIoIq_Qces05Trjq7QxWaLGcPWlXBrC_hms123uQnRzw6aAqkEm-6a8W63v56Cb3JJsytzggXT7G10CWwJrnH1C-ktej3YMcO7-3qKfn3_drk-x9ufPzbrr1vsuBIFC664lxTIYC3r7eA7oPWRoR1a5SwMnZaEEiGk9j2hnA26194q2Vkhey_YKfpy0N3P_Q68g1iSHc0-hV21ayYbzP-dGK7N1XRrKNWSd5pVhU_3Cmn6PUMuZheyg3G0EaY5G0aFFK2iehn28Rn0ZppTrPtVlGKk6xRdBD88tfTo5eHWFdAeAC5NOScYHiGUmCVQcwjU1EDN30DNMls_I7lQ6sGnZa0wvkxlB2quc-IVpH-2X2D9AZI9tLQ
CitedBy_id crossref_primary_10_1002_imt2_70050
crossref_primary_10_1016_j_cell_2025_08_017
crossref_primary_10_3389_fimmu_2025_1655730
crossref_primary_10_1016_j_ejca_2025_115572
crossref_primary_10_1038_s41392_025_02260_5
crossref_primary_10_3389_fonc_2025_1613332
crossref_primary_10_1002_eji_70041
crossref_primary_10_1016_j_apsb_2025_09_027
crossref_primary_10_1016_j_bbcan_2025_189312
crossref_primary_10_3390_biomedicines13030539
crossref_primary_10_1016_j_canlet_2025_217584
crossref_primary_10_1016_j_trecan_2025_03_003
crossref_primary_10_1016_j_semcancer_2025_09_005
crossref_primary_10_1016_j_imlet_2025_107064
crossref_primary_10_1515_mr_2025_0037
crossref_primary_10_1007_s00262_025_04108_x
crossref_primary_10_1016_j_canlet_2025_217890
crossref_primary_10_1038_s41598_025_05087_w
crossref_primary_10_3389_fimmu_2025_1543322
crossref_primary_10_3389_fimmu_2025_1674174
Cites_doi 10.1158/0008-5472.CAN-06-0217
10.1126/sciimmunol.abc6259
10.1016/S1074-7613(00)80588-9
10.1038/nature23469
10.1038/ncomms9327
10.4049/jimmunol.169.1.424
10.1084/jem.20191172
10.1016/j.celrep.2021.109422
10.1038/nbt.3820
10.1016/j.ccr.2009.08.021
10.1038/s41590-021-00943-z
10.4049/jimmunol.171.6.2797
10.1038/s41586-022-05297-6
10.1038/s41586-020-2015-4
10.1038/s41586-021-03531-1
10.1186/gb-2010-11-3-r25
10.1038/s41587-020-0439-x
10.12688/f1000research.8923.1
10.1084/jem.20021761
10.1038/s41586-019-1914-8
10.1038/nature12526
10.1038/s41586-019-1922-8
10.1016/j.immuni.2007.04.009
10.1016/j.ajpath.2011.03.007
10.1186/1471-213X-9-49
10.1038/nmeth.3869
10.1016/j.cell.2018.02.052
10.1016/j.bbmt.2019.05.030
10.1038/bjc.2015.145
10.1016/j.immuni.2005.02.007
10.1016/j.jhep.2018.09.003
10.1186/1471-2105-14-7
10.1084/jem.20100052
10.1038/s41467-020-19973-6
10.1371/journal.pcbi.1006701
10.1038/nature23676
10.1084/jem.185.1.99
10.3389/fmicb.2020.550420
10.1080/2162402X.2017.1378844
10.1038/ncomms3680
10.1038/nature24029
10.1084/jem.20232148
10.1038/nature16965
10.1038/nprot.2017.044
10.1038/ni.3078
10.4049/jimmunol.2001304
10.1158/0008-5472.CAN-17-1987
10.1126/science.aam5809
10.1038/s41586-022-05395-5
10.1126/science.1194597
10.1371/journal.pcbi.1012265
10.1016/j.cell.2015.05.044
10.1038/s43018-021-00232-6
10.1038/35018581
10.1093/nar/gks1219
10.1038/s41586-019-1906-8
10.1016/j.molimm.2017.05.008
10.1016/S1074-7613(00)80589-0
10.1126/science.abf9419
10.14806/ej.17.1.200
10.1093/bioinformatics/btw777
10.1038/s41586-024-07746-w
10.1038/ni.3057
10.1016/j.ccell.2018.03.014
10.1084/jem.183.4.1461
10.1172/JCI67428
10.1158/2159-8290.CD-17-1134
10.1038/nri.2016.95
10.1093/nar/gkab1049
10.1093/bioinformatics/btv359
10.1016/S1074-7613(02)00397-7
10.1038/s41568-019-0144-6
10.1016/j.immuni.2014.06.016
10.1038/35017610
10.1093/nar/gkv1507
10.1038/s41586-020-03147-x
10.1016/j.cell.2020.03.031
10.1016/j.ccell.2017.07.007
10.1038/nm.1984
10.1016/j.immuni.2011.10.015
10.1016/j.ccell.2022.01.003
10.1016/j.immuni.2005.09.015
10.1158/2326-6066.CIR-19-0775
10.1371/journal.pcbi.1007977
10.1038/s41598-018-21589-2
10.1016/j.immuni.2020.02.009
ContentType Journal Article
Copyright The Author(s) 2025
2025. The Author(s).
Copyright Nature Publishing Group Feb 27, 2025
The Author(s) 2025 2025
Copyright_xml – notice: The Author(s) 2025
– notice: 2025. The Author(s).
– notice: Copyright Nature Publishing Group Feb 27, 2025
– notice: The Author(s) 2025 2025
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QG
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7TG
7TK
7TM
7TO
7U9
8FD
C1K
FR3
H94
K9.
KL.
M7N
NAPCQ
P64
RC3
SOI
7X8
5PM
DOI 10.1038/s41586-024-08426-5
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Immunology Abstracts
Meteorological & Geoastrophysical Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Meteorological & Geoastrophysical Abstracts - Academic
Algology Mycology and Protozoology Abstracts (Microbiology C)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
Ecology Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Entomology Abstracts
Nursing & Allied Health Premium
Genetics Abstracts
Meteorological & Geoastrophysical Abstracts
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Immunology Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Environment Abstracts
Meteorological & Geoastrophysical Abstracts - Academic
MEDLINE - Academic
DatabaseTitleList
Virology and AIDS Abstracts
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Physics
EISSN 1476-4687
EndPage 1084
ExternalDocumentID PMC11864983
39814891
10_1038_s41586_024_08426_5
Genre Journal Article
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: R01 DK132244
– fundername: NIDDK NIH HHS
  grantid: R01 DK126871
– fundername: NIAID NIH HHS
  grantid: R01 AI151599
– fundername: NIAID NIH HHS
  grantid: R01 AI095466
– fundername: NIAID NIH HHS
  grantid: K99 AI180354
– fundername: NIAID NIH HHS
  grantid: U01 AI095608
– fundername: NIAMS NIH HHS
  grantid: R01 AR070116
– fundername: NIAID NIH HHS
  grantid: R01 AI172027
– fundername: NCI NIH HHS
  grantid: P30 CA008748
– fundername: NCI NIH HHS
  grantid: R01 CA262516
GroupedDBID ---
--Z
-DZ
-ET
-~X
.55
.CO
.XZ
07C
0R~
123
186
1OL
29M
2KS
39C
5RE
6TJ
70F
7RV
85S
8WZ
97F
A6W
A7Z
AAEEF
AAHBH
AAHTB
AAIKC
AAKAB
AAMNW
AASDW
AAYEP
AAYZH
AAZLF
ABDQB
ABFSI
ABIVO
ABJNI
ABLJU
ABOCM
ABPEJ
ABPPZ
ABWJO
ABZEH
ACBEA
ACBWK
ACGFO
ACGFS
ACGOD
ACIWK
ACKOT
ACMJI
ACNCT
ACPRK
ACWUS
ADBBV
ADFRT
ADUKH
AENEX
AFBBN
AFFNX
AFLOW
AFRAH
AFSHS
AGAYW
AGHSJ
AGHTU
AGOIJ
AGSOS
AHMBA
AHSBF
AIDUJ
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
ARAPS
ARMCB
ASPBG
ATCPS
ATWCN
AVWKF
AXYYD
AZFZN
BENPR
BHPHI
BIN
BKKNO
C6C
CJ0
CS3
DU5
E.-
E.L
EAP
EBS
EE.
EPS
EXGXG
F5P
FAC
FEDTE
FQGFK
FSGXE
HCIFZ
HG6
HVGLF
HZ~
IAO
ICQ
IEA
IEP
IGS
IH2
IHR
INH
IOF
IPY
KOO
L7B
LGEZI
LOTEE
LSO
M0K
M2O
M7P
N9A
NADUK
NEPJS
NXXTH
O9-
OBC
ODYON
OES
OHH
OMK
OVD
P2P
PKN
PV9
RND
RNS
RNT
RNTTT
RXW
SC5
SHXYY
SIXXV
SJN
SNYQT
SOJ
TAE
TAOOD
TBHMF
TDRGL
TN5
TSG
TWZ
U5U
UIG
UKR
UMD
UQL
VQA
VVN
WH7
X7M
XIH
XKW
XZL
Y6R
YAE
YCJ
YFH
YIF
YIN
YJ6
YNT
YOC
YQT
YR2
YR5
YXB
YZZ
Z5M
ZCA
~02
~88
~KM
0WA
AARCD
AAYXX
ABFSG
ABUFD
ACSTC
AEZWR
AFANA
AFHIU
AFKWF
AGSTI
AHWEU
AIXLP
ALPWD
ATHPR
CITATION
NAPCQ
NFIDA
TEORI
TUS
.-4
.GJ
.HR
00M
08P
1CY
1VR
1VW
2XV
354
3EH
3O-
4.4
41X
41~
42X
4R4
53G
663
79B
7X2
7X7
7XC
88E
88I
8AF
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
8G5
8R4
8R5
97L
9M8
A8Z
AAJYS
AAKAS
AAVBQ
ABAWZ
ABDBF
ABDPE
ABEFU
ABJCF
ABNNU
ABUWG
ACBNA
ACBTR
ACRPL
ACTDY
ACUHS
ADGHP
ADNMO
ADRHT
ADXHL
ADYSU
ADZCM
AETEA
AEUYN
AFFDN
AFHKK
AFKRA
AGCDD
AGGDT
AGNAY
AGQPQ
AIDAL
AIYXT
AJUXI
APEBS
ARTTT
AZQEC
B0M
BBNVY
BCR
BCU
BDKGC
BEC
BES
BGLVJ
BKEYQ
BKOMP
BKSAR
BLC
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
D1I
D1J
D1K
DB5
DO4
DWQXO
EAD
EAS
EAZ
EBC
EBD
EBO
ECC
ECM
EIF
EJD
EMB
EMF
EMH
EMK
EMOBN
EPL
ESE
ESN
ESX
EX3
FA8
FYUFA
GNUQQ
GUQSH
HMCUK
I-F
INR
ISR
ITC
J5H
K6-
KB.
L-9
L6V
LK5
LK8
M1P
M2M
M2P
M7R
M7S
MVM
N4W
NEJ
NPM
OHT
P-O
P62
PATMY
PCBAR
PDBOC
PEA
PHGZM
PHGZT
PJZUB
PM3
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PSYQQ
PTHSS
PYCSY
Q2X
QS-
R05
R4F
RHI
S0X
SJFOW
SKT
SV3
TH9
TUD
UBY
UHB
UKHRP
USG
VOH
WOW
X7L
XOL
YQI
YQJ
YV5
YXA
YYP
YYQ
ZCG
ZE2
ZGI
ZHY
ZKB
ZY4
~7V
~8M
~G0
7QG
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7TG
7TK
7TM
7TO
7U9
8FD
C1K
FR3
H94
K9.
KL.
M7N
P64
RC3
SOI
7X8
5PM
ID FETCH-LOGICAL-c475t-5474d61e0faa3bafd9e19e10f2f27caef9860105568db0143f8b8da769a56bd53
ISICitedReferencesCount 32
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001396188600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0028-0836
1476-4687
IngestDate Tue Nov 04 02:05:07 EST 2025
Fri Sep 05 11:43:08 EDT 2025
Tue Oct 07 07:07:50 EDT 2025
Fri Aug 01 03:41:36 EDT 2025
Sat Nov 29 08:11:01 EST 2025
Tue Nov 18 21:18:34 EST 2025
Thu Feb 27 03:09:37 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8052
Language English
License 2025. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c475t-5474d61e0faa3bafd9e19e10f2f27caef9860105568db0143f8b8da769a56bd53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-6153-8793
0000-0003-2885-1133
0000-0002-3655-916X
0000-0002-2956-223X
0000-0002-4352-7748
0000-0003-4170-8796
0000-0003-1735-2347
0000-0002-0406-017X
0000-0002-7270-5136
0000-0003-4153-4036
0000-0001-9218-4086
0000-0002-4708-5211
0000-0002-1518-5111
0000-0001-6885-6145
0000-0002-1753-4100
0009-0001-4436-2746
0000-0001-8683-8477
0000-0002-3098-2629
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC11864983
PMID 39814891
PQID 3173099713
PQPubID 40569
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_11864983
proquest_miscellaneous_3156527185
proquest_journals_3173099713
pubmed_primary_39814891
crossref_primary_10_1038_s41586_024_08426_5
crossref_citationtrail_10_1038_s41586_024_08426_5
springer_journals_10_1038_s41586_024_08426_5
PublicationCentury 2000
PublicationDate 2025-02-27
PublicationDateYYYYMMDD 2025-02-27
PublicationDate_xml – month: 02
  year: 2025
  text: 2025-02-27
  day: 27
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationSubtitle International weekly journal of science
PublicationTitle Nature (London)
PublicationTitleAbbrev Nature
PublicationTitleAlternate Nature
PublicationYear 2025
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References 8426_CR77
TN Schumacher (8426_CR15) 2022; 375
A Wallrapp (8426_CR18) 2017; 549
BJ Callahan (8426_CR62) 2016; 13
8426_CR72
BJ Raphael (8426_CR66) 2017; 32
M Arifuzzaman (8426_CR56) 2024; 221
AB Rodriguez (8426_CR71) 2021; 36
M Zhang (8426_CR49) 2020; 181
MD Robinson (8426_CR86) 2010; 11
J Schmitz (8426_CR39) 2005; 23
X Zhao (8426_CR29) 2003; 171
F Qi (8426_CR46) 2017; 87
K Kabashima (8426_CR47) 2005; 22
8426_CR35
D Alonso-Curbelo (8426_CR44) 2021; 590
AC Berger (8426_CR67) 2018; 33
M Lukashev (8426_CR12) 2006; 66
8426_CR23
L-Y Hung (8426_CR48) 2020; 5
PA Ewels (8426_CR59) 2020; 38
8426_CR61
F Petitprez (8426_CR5) 2020; 577
DJ McCarthy (8426_CR81) 2017; 33
N Nouri (8426_CR78) 2020; 16
DL Drayton (8426_CR11) 2003; 197
A Alam (8426_CR50) 2022; 40
CJ Oliphant (8426_CR24) 2014; 41
Y Huang (8426_CR31) 2015; 16
D Meier (8426_CR27) 2007; 26
J Calderaro (8426_CR74) 2019; 70
M Mounir (8426_CR85) 2019; 15
C Sautès-Fridman (8426_CR3) 2019; 19
A Colaprico (8426_CR83) 2016; 44
M Lochner (8426_CR14) 2010; 208
EY Chiang (8426_CR70) 2009; 15
AD Howard (8426_CR45) 2000; 406
P Bailey (8426_CR64) 2016; 531
TCGA Network (8426_CR68) 2015; 161
A Kratz (8426_CR1) 1996; 183
CS Carlson (8426_CR76) 2013; 4
N Hiraoka (8426_CR9) 2015; 112
J Haybaeck (8426_CR54) 2009; 16
S Hänzelmann (8426_CR80) 2013; 14
M Zhang (8426_CR30) 2020; 11
C Alt (8426_CR38) 2019; 25
8426_CR53
KM Ansel (8426_CR25) 2000; 406
S Pushalkar (8426_CR36) 2018; 8
ES Cohen (8426_CR37) 2015; 6
R Cabrita (8426_CR4) 2020; 577
JA Moral (8426_CR16) 2020; 579
8426_CR52
JK Bando (8426_CR69) 2014; 16
F Posch (8426_CR73) 2017; 7
8426_CR51
IC Scott (8426_CR2) 2018; 8
TC Silva (8426_CR84) 2016; 5
V Cardoso (8426_CR19) 2017; 549
C Gu-Trantien (8426_CR8) 2013; 123
S Sawa (8426_CR40) 2010; 330
PD Tommaso (8426_CR58) 2017; 35
Y Huang (8426_CR32) 2018; 359
D Straub (8426_CR60) 2020; 11
CSN Klose (8426_CR17) 2017; 549
L Vanhersecke (8426_CR75) 2021; 2
A Peters (8426_CR42) 2011; 35
8426_CR43
J Liu (8426_CR65) 2018; 173
D Coppola (8426_CR7) 2011; 179
MN Sarafi (8426_CR28) 1997; 185
AM Tsou (8426_CR20) 2022; 611
JC Nussbaum (8426_CR22) 2013; 502
C Quast (8426_CR63) 2013; 41
KJ Jarick (8426_CR21) 2022; 611
PD Rennert (8426_CR13) 1998; 9
Q Pu (8426_CR33) 2021; 207
F Cunningham (8426_CR82) 2021; 50
SA Luther (8426_CR26) 2002; 169
S Wirtz (8426_CR55) 2017; 12
DF Zegarra-Ruiz (8426_CR57) 2021; 594
NT Gupta (8426_CR79) 2015; 31
A Ikeda (8426_CR41) 2020; 8
BA Helmink (8426_CR6) 2020; 577
RR Ricardo-Gonzalez (8426_CR34) 2020; 217
FY Liew (8426_CR10) 2016; 16
References_xml – volume: 66
  start-page: 9617
  year: 2006
  ident: 8426_CR12
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-0217
– volume: 5
  year: 2020
  ident: 8426_CR48
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.abc6259
– ident: 8426_CR52
  doi: 10.1016/S1074-7613(00)80588-9
– volume: 549
  start-page: 277
  year: 2017
  ident: 8426_CR19
  publication-title: Nature
  doi: 10.1038/nature23469
– volume: 6
  start-page: 1
  year: 2015
  ident: 8426_CR37
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms9327
– volume: 169
  start-page: 424
  year: 2002
  ident: 8426_CR26
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.169.1.424
– volume: 217
  start-page: 171
  year: 2020
  ident: 8426_CR34
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20191172
– volume: 36
  start-page: 109422
  year: 2021
  ident: 8426_CR71
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.109422
– volume: 35
  start-page: 316
  year: 2017
  ident: 8426_CR58
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.3820
– volume: 16
  start-page: 295
  year: 2009
  ident: 8426_CR54
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.08.021
– ident: 8426_CR43
  doi: 10.1038/s41590-021-00943-z
– volume: 171
  start-page: 2797
  year: 2003
  ident: 8426_CR29
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.171.6.2797
– volume: 611
  start-page: 787
  year: 2022
  ident: 8426_CR20
  publication-title: Nature
  doi: 10.1038/s41586-022-05297-6
– volume: 579
  start-page: 790
  year: 2020
  ident: 8426_CR16
  publication-title: Nature
  doi: 10.1038/s41586-020-2015-4
– volume: 594
  start-page: 413
  year: 2021
  ident: 8426_CR57
  publication-title: Nature
  doi: 10.1038/s41586-021-03531-1
– volume: 11
  year: 2010
  ident: 8426_CR86
  publication-title: Genome Biol.
  doi: 10.1186/gb-2010-11-3-r25
– volume: 38
  start-page: 276
  year: 2020
  ident: 8426_CR59
  publication-title: Nat. Biotechnol.
  doi: 10.1038/s41587-020-0439-x
– volume: 5
  start-page: 1542
  year: 2016
  ident: 8426_CR84
  publication-title: F1000Res.
  doi: 10.12688/f1000research.8923.1
– volume: 197
  start-page: 1153
  year: 2003
  ident: 8426_CR11
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20021761
– volume: 577
  start-page: 561
  year: 2020
  ident: 8426_CR4
  publication-title: Nature
  doi: 10.1038/s41586-019-1914-8
– volume: 502
  start-page: 245
  year: 2013
  ident: 8426_CR22
  publication-title: Nature
  doi: 10.1038/nature12526
– volume: 577
  start-page: 549
  year: 2020
  ident: 8426_CR6
  publication-title: Nature
  doi: 10.1038/s41586-019-1922-8
– volume: 26
  start-page: 643
  year: 2007
  ident: 8426_CR27
  publication-title: Immunity
  doi: 10.1016/j.immuni.2007.04.009
– volume: 179
  start-page: 37
  year: 2011
  ident: 8426_CR7
  publication-title: Am. J. Pathol.
  doi: 10.1016/j.ajpath.2011.03.007
– ident: 8426_CR53
  doi: 10.1186/1471-213X-9-49
– volume: 13
  start-page: 581
  year: 2016
  ident: 8426_CR62
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.3869
– volume: 173
  start-page: 400
  year: 2018
  ident: 8426_CR65
  publication-title: Cell
  doi: 10.1016/j.cell.2018.02.052
– volume: 25
  start-page: 1475
  year: 2019
  ident: 8426_CR38
  publication-title: Biol. Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2019.05.030
– volume: 112
  start-page: 1782
  year: 2015
  ident: 8426_CR9
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2015.145
– volume: 22
  start-page: 439
  year: 2005
  ident: 8426_CR47
  publication-title: Immunity
  doi: 10.1016/j.immuni.2005.02.007
– volume: 70
  start-page: 58
  year: 2019
  ident: 8426_CR74
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2018.09.003
– volume: 14
  start-page: 7
  year: 2013
  ident: 8426_CR80
  publication-title: BMC Bioinform.
  doi: 10.1186/1471-2105-14-7
– volume: 208
  start-page: 125
  year: 2010
  ident: 8426_CR14
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20100052
– volume: 11
  year: 2020
  ident: 8426_CR30
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19973-6
– volume: 15
  start-page: e1006701
  year: 2019
  ident: 8426_CR85
  publication-title: PLoS Comput. Biol.
  doi: 10.1371/journal.pcbi.1006701
– volume: 549
  start-page: 282
  year: 2017
  ident: 8426_CR17
  publication-title: Nature
  doi: 10.1038/nature23676
– volume: 185
  start-page: 99
  year: 1997
  ident: 8426_CR28
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.185.1.99
– volume: 11
  start-page: 550420
  year: 2020
  ident: 8426_CR60
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2020.550420
– volume: 7
  start-page: e1378844
  year: 2017
  ident: 8426_CR73
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1378844
– volume: 4
  year: 2013
  ident: 8426_CR76
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms3680
– volume: 549
  start-page: 351
  year: 2017
  ident: 8426_CR18
  publication-title: Nature
  doi: 10.1038/nature24029
– volume: 221
  start-page: e20232148
  year: 2024
  ident: 8426_CR56
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20232148
– volume: 531
  start-page: 47
  year: 2016
  ident: 8426_CR64
  publication-title: Nature
  doi: 10.1038/nature16965
– volume: 12
  start-page: 1295
  year: 2017
  ident: 8426_CR55
  publication-title: Nat. Protoc.
  doi: 10.1038/nprot.2017.044
– volume: 16
  start-page: 161
  year: 2015
  ident: 8426_CR31
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.3078
– volume: 207
  start-page: 257
  year: 2021
  ident: 8426_CR33
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.2001304
– ident: 8426_CR72
  doi: 10.1158/0008-5472.CAN-17-1987
– volume: 359
  start-page: 114
  year: 2018
  ident: 8426_CR32
  publication-title: Science
  doi: 10.1126/science.aam5809
– volume: 611
  start-page: 794
  year: 2022
  ident: 8426_CR21
  publication-title: Nature
  doi: 10.1038/s41586-022-05395-5
– volume: 330
  start-page: 665
  year: 2010
  ident: 8426_CR40
  publication-title: Science
  doi: 10.1126/science.1194597
– ident: 8426_CR77
  doi: 10.1371/journal.pcbi.1012265
– volume: 161
  start-page: 1681
  year: 2015
  ident: 8426_CR68
  publication-title: Cell
  doi: 10.1016/j.cell.2015.05.044
– volume: 2
  start-page: 794
  year: 2021
  ident: 8426_CR75
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-021-00232-6
– volume: 406
  start-page: 309
  year: 2000
  ident: 8426_CR25
  publication-title: Nature
  doi: 10.1038/35018581
– volume: 41
  start-page: D590
  year: 2013
  ident: 8426_CR63
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gks1219
– volume: 577
  start-page: 556
  year: 2020
  ident: 8426_CR5
  publication-title: Nature
  doi: 10.1038/s41586-019-1906-8
– volume: 87
  start-page: 284
  year: 2017
  ident: 8426_CR46
  publication-title: Mol. Immunol.
  doi: 10.1016/j.molimm.2017.05.008
– volume: 9
  start-page: 71
  year: 1998
  ident: 8426_CR13
  publication-title: Immunity
  doi: 10.1016/S1074-7613(00)80589-0
– volume: 375
  start-page: eabf9419
  year: 2022
  ident: 8426_CR15
  publication-title: Science
  doi: 10.1126/science.abf9419
– ident: 8426_CR61
  doi: 10.14806/ej.17.1.200
– volume: 33
  start-page: btw777
  year: 2017
  ident: 8426_CR81
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btw777
– ident: 8426_CR23
  doi: 10.1038/s41586-024-07746-w
– volume: 16
  start-page: 153
  year: 2014
  ident: 8426_CR69
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.3057
– volume: 33
  start-page: 690
  year: 2018
  ident: 8426_CR67
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.03.014
– volume: 183
  start-page: 1461
  year: 1996
  ident: 8426_CR1
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.183.4.1461
– volume: 123
  start-page: 2873
  year: 2013
  ident: 8426_CR8
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI67428
– volume: 8
  start-page: 403
  year: 2018
  ident: 8426_CR36
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-17-1134
– volume: 16
  start-page: 676
  year: 2016
  ident: 8426_CR10
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri.2016.95
– volume: 50
  start-page: D988
  year: 2021
  ident: 8426_CR82
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkab1049
– volume: 31
  start-page: 3356
  year: 2015
  ident: 8426_CR79
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btv359
– ident: 8426_CR51
  doi: 10.1016/S1074-7613(02)00397-7
– volume: 19
  start-page: 307
  year: 2019
  ident: 8426_CR3
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-019-0144-6
– volume: 41
  start-page: 283
  year: 2014
  ident: 8426_CR24
  publication-title: Immunity
  doi: 10.1016/j.immuni.2014.06.016
– volume: 406
  start-page: 70
  year: 2000
  ident: 8426_CR45
  publication-title: Nature
  doi: 10.1038/35017610
– volume: 44
  start-page: e71
  year: 2016
  ident: 8426_CR83
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkv1507
– volume: 590
  start-page: 642
  year: 2021
  ident: 8426_CR44
  publication-title: Nature
  doi: 10.1038/s41586-020-03147-x
– volume: 181
  start-page: 637
  year: 2020
  ident: 8426_CR49
  publication-title: Cell
  doi: 10.1016/j.cell.2020.03.031
– volume: 32
  start-page: 185
  year: 2017
  ident: 8426_CR66
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.07.007
– volume: 15
  start-page: 766
  year: 2009
  ident: 8426_CR70
  publication-title: Nat. Med.
  doi: 10.1038/nm.1984
– volume: 35
  start-page: 986
  year: 2011
  ident: 8426_CR42
  publication-title: Immunity
  doi: 10.1016/j.immuni.2011.10.015
– volume: 40
  start-page: 153
  year: 2022
  ident: 8426_CR50
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.01.003
– volume: 23
  start-page: 479
  year: 2005
  ident: 8426_CR39
  publication-title: Immunity
  doi: 10.1016/j.immuni.2005.09.015
– volume: 8
  start-page: 724
  year: 2020
  ident: 8426_CR41
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-19-0775
– volume: 16
  start-page: e1007977
  year: 2020
  ident: 8426_CR78
  publication-title: PLoS Comput. Biol.
  doi: 10.1371/journal.pcbi.1007977
– volume: 8
  year: 2018
  ident: 8426_CR2
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-018-21589-2
– ident: 8426_CR35
  doi: 10.1016/j.immuni.2020.02.009
SSID ssj0005174
Score 2.5944617
Snippet Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although...
Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically infamed tissues, including tumours. Although...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1076
SubjectTerms 13/51
14/19
14/63
38/39
38/91
45/91
631/250/2504/2506
631/250/580
631/67/1504/1713
64/110
64/60
96/31
Adenocarcinoma
Alarmins - immunology
Alarmins - metabolism
Animals
Antigens
Carcinoma, Pancreatic Ductal - immunology
Carcinoma, Pancreatic Ductal - pathology
Carcinoma, Pancreatic Ductal - therapy
Colitis
Colitis - immunology
Colitis - pathology
Female
Humanities and Social Sciences
Humans
Immunity (Disease)
Immunity, Innate
Immunotherapy
Inflammation
Inflammation - immunology
Inflammation - pathology
Inflammatory bowel disease
Interleukin-33 - deficiency
Interleukin-33 - genetics
Interleukin-33 - immunology
Interleukin-33 - metabolism
Intestinal microflora
Lymphocytes - cytology
Lymphocytes - immunology
Lymphoid cells
Lymphotoxin
Male
Medical prognosis
Mice
Mice, Inbred C57BL
multidisciplinary
Pancreatic cancer
Pancreatic Neoplasms - immunology
Pancreatic Neoplasms - pathology
Pancreatic Neoplasms - therapy
Recombinant Proteins - immunology
Science
Science (multidisciplinary)
Tertiary Lymphoid Structures - immunology
Tertiary Lymphoid Structures - pathology
Toxins
Tumors
Title IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
URI https://link.springer.com/article/10.1038/s41586-024-08426-5
https://www.ncbi.nlm.nih.gov/pubmed/39814891
https://www.proquest.com/docview/3173099713
https://www.proquest.com/docview/3156527185
https://pubmed.ncbi.nlm.nih.gov/PMC11864983
Volume 638
WOSCitedRecordID wos001396188600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAQT
  databaseName: Nature
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: RNT
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://www.nature.com
  providerName: Nature Publishing
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6ARIviI1bYUxBQghUIprE8eVxmjZtUikIdVLhJbIdR4uo0m5pq8Ejv5zj2EnadaDxgFRFlePGTr_Px8f2uSD0OoxUIAmlvqIp9zGRmS8lgeGuMwziL-hrXSE9oMMhG4_5507nV-0Ls5zQomBXV3z2X6GGMgDbuM7-A9zNQ6EAvgPocAXY4Xor4E8HfhT5xl9hKYw6eTo4DI3RVQog9owFQG4M5SY_AMZpnvZsANnFpbYG5UCCSo1UxhxMOdNdp7wOqyCgq0lA2l0EoIuwGbA_ilLMxfdG3H_TUk4XaXVKdCBNbtCfonEP-iqq1N-9kxxm6_N8cxs7v8jNvkHpjp_d_kRo_b3pikjFlAAJ3LSqbyhzcphEbIVwJtXCimCFVSq5UeLb-O4l6CHMWFNjE6g2JH7czm_1mf7wU3J8Nhgko6Px6M3swjeZx8wJvUvDsoXuhDTmRjJ-GY5aMyEbybvpsXO8gmY_bDa6rtxsrFg2DW-vnb5XSs3oIXrgViPegWXRDuroYhfdq6yCVbmLdpzkL723Ljz5u0doeI1gXkUwzxLMqwnm1QTzWoJBHa8lmGcJ9hidHR-NDk98l5XDV5jGcz_GFKck0P1MiEiKLOU6gE8_C7OQKqEzzohNu8pSaaJHZkyyVFDCRUxkGkdP0HYxLfQz5JEoDBQXnEiuMMGBTGGBoYJQg-amMNddFNR_Z6JcyHqTOWWSVKYTEUssBAlAkFQQJHEX9ZrfzGzAlr_W3qtRStwYLhNQqSPjUB5EXfSquQ3jyJyliUJPF6YOrIRCUOzgEU8tqE1zEWcBZjzoIrYGd1PBhHRfv1Pk51Vod1juE8wZNPy-Zkbbrz-_xvNb9PMFut8Ozz20DeDrl-iuWs7z8nIfbdEx26-o_xvFHcwf
linkProvider Nature Publishing
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=IL-33-activated+ILC2s+induce+tertiary+lymphoid+structures+in+pancreatic+cancer&rft.jtitle=Nature+%28London%29&rft.au=Amisaki%2C+Masataka&rft.au=Zebboudj%2C+Abderezak&rft.au=Yano%2C+Hiroshi&rft.au=Zhang%2C+Siqi+Linsey&rft.date=2025-02-27&rft.issn=1476-4687&rft.eissn=1476-4687&rft.volume=638&rft.issue=8052&rft.spage=1076&rft_id=info:doi/10.1038%2Fs41586-024-08426-5&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-0836&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-0836&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-0836&client=summon